Lowest-Rated StocksLowest-RatedNYSE:NVS Novartis (NVS) Stock Price, News & Analysis $115.89 +2.39 (+2.10%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$115.50 -0.39 (-0.34%) As of 08/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novartis Stock (NYSE:NVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novartis alerts:Sign Up Key Stats Today's Range$114.38▼$116.0050-Day Range$112.47▼$123.8352-Week Range$96.06▼$124.83Volume1.33 million shsAverage Volume2.16 million shsMarket Capitalization$244.80 billionP/E Ratio16.87Dividend Yield2.24%Price Target$123.67Consensus RatingHold Company Overview Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Read More Novartis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreNVS MarketRank™: Novartis scored higher than 36% of companies evaluated by MarketBeat, and ranked 725th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingNovartis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 6 hold ratings, and 3 sell ratings.Amount of Analyst CoverageNovartis has received no research coverage in the past 90 days.Read more about Novartis' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth4.26% Earnings GrowthEarnings for Novartis are expected to grow by 4.26% in the coming year, from $8.45 to $8.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 16.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 16.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.88.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.22% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently increased by 4.68%, indicating that investor sentiment is decreasing. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldNovartis pays a meaningful dividend of 2.29%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 37.85%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 29.51% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.22% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novartis has recently increased by 4.68%, indicating that investor sentiment is decreasing. News and Social Media3.4 / 5News Sentiment1.16 News SentimentNovartis has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 35 news articles for Novartis this week, compared to 19 articles on an average week.Search Interest12 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address NVS Stock News HeadlinesAvidity Biosciences jumps on report of Novartis takeover approachAugust 6 at 7:06 PM | msn.comAvidity Biosciences stock soars on Novartis takeover approach reportAugust 6 at 7:06 PM | finance.yahoo.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant PremiumAugust 6 at 7:06 PM | msn.comAvidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover DealAugust 6 at 7:06 PM | msn.comNovartis weighs deal for biotech Avidity Biosciences, FT reportsAugust 6 at 11:41 AM | reuters.comQ1 Earnings Forecast for Novartis Issued By Zacks ResearchAugust 5 at 2:51 AM | americanbankingnews.comBernstein Maintains a Buy Rating on Novartis (NVS), Sets a CHF108 PTAugust 4, 2025 | msn.comSee More Headlines NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $97.31 at the beginning of 2025. Since then, NVS shares have increased by 19.1% and is now trading at $115.8870. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) announced its quarterly earnings results on Thursday, July, 17th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. The business's quarterly revenue was up 12.3% on a year-over-year basis. Read the conference call transcript. Does Novartis have any subsidiaries? Novartis subsidiaries include these companies: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and more. Who are Novartis' major shareholders? Top institutional investors of Novartis include Envestnet Asset Management Inc. (0.08%), Scharf Investments LLC (0.06%), Chevy Chase Trust Holdings LLC (0.05%) and Truist Financial Corp (0.04%). How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include BlackRock (BLK), Broadcom (AVGO), UnitedHealth Group (UNH), ServiceNow (NOW), Humana (HUM), TotalEnergies (TTE) and American Water Works (AWK). Company Calendar Last Earnings7/17/2025Today8/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Large Cap Pharma Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees75,883Year Founded1996Price Target and Rating Average Price Target for Novartis$123.67 High Price Target$130.00 Low Price Target$120.00 Potential Upside/Downside+6.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$6.87 Trailing P/E Ratio16.87 Forward P/E Ratio13.71 P/E Growth1.66Net Income$11.94 billion Net Margins25.64% Pretax Margin29.30% Return on Equity41.08% Return on Assets16.83% Debt Debt-to-Equity Ratio0.53 Current Ratio0.82 Quick Ratio0.62 Sales & Book Value Annual Sales$55.19 billion Price / Sales4.44 Cash Flow$10.54 per share Price / Cash Flow11.00 Book Value$19.91 per share Price / Book5.82Miscellaneous Outstanding Shares2,112,422,000Free Float2,112,211,000Market Cap$244.80 billion OptionableOptionable Beta0.62 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NYSE:NVS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.